Patents Assigned to OncoTherapy Science
  • CDCA1 PEPTIDE AND PHARMACEUTICAL AGENT COMPRISING THE SAME
    Publication number: 20110152199
    Abstract: The present invention provides the peptide of (A) or (B) below, and methods of using the peptide: (A) a peptide including the amino acid sequence of SEQ ID NO: 1 or 2, (B) a peptide which includes the amino acid sequence of SEQ ID NO: 1 or 2, wherein one, two, or several amino acid(s) are substituted, deleted, inserted, and/or added, and wherein the peptide shows killer T cell-inducing activity.
    Type: Application
    Filed: June 13, 2008
    Publication date: June 23, 2011
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yasuharu Nishimura, Michuko Harao, Takuya Tsunoda, Yusuke Nakamura
  • GENES AND POLYPEPTIDES RELATING TO BREAST CANCERS
    Publication number: 20110135647
    Abstract: The present application provides novel human genes A7322, whose expression is markedly elevated in breast cancer. The present application also provides human genes F3374 whose expression is markedly elevated in breast cancer. These genes and polypeptides encoded thereby can be used, for example, in the diagnosis of breast cancer, and as target molecules for developing drugs against breast cancer. The invention features methods of screening for modulators of the kinase activity of PBK/TOPK. The invention further provides methods of screening for agents to prevent or treat cancer, such as breast cancer.
    Type: Application
    Filed: August 10, 2007
    Publication date: June 9, 2011
    Applicant: Oncotherapy Science Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri, Shuichi Nakatsura
  • PROSTATE CANCER RELATED GENE STYK1
    Publication number: 20110135654
    Abstract: The present invention provides methods for detecting and diagnosing cancer, which method involves the determination of the expression level of the STYK1 gene. The gene was discovered to discriminate cancer cells from normal cells. Furthermore, the present invention provides methods of screening for therapeutic agents useful in the treatment of cancer, methods for treating cancer, and methods for vaccinating a subject against cancer. Moreover, the present invention provides siRNAs targeting the STYK1 gene, which are suggested to be useful in the treatment of cancer.
    Type: Application
    Filed: August 8, 2007
    Publication date: June 9, 2011
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yusuke Nakamura, Hidewaki Nakagawa, Shuichi Nakatsuru
  • Screening and therapeutic method for NSCLC targeting CDCA1-KNTC2 complex
    Patent number: 7943295
    Abstract: The present invention is based on the observation that the co-activation of CDCA1 and KNTC2, and their cognate interactions, play significant roles in lung-cancer progression and that methods of inhibiting the complex can be used to treat non-small-cell lung cancer.
    Type: Grant
    Filed: July 19, 2006
    Date of Patent: May 17, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Genes and polypeptides relating to human pancreatic cancers
    Patent number: 7943730
    Abstract: The present application provides novel human genes C1958V1 or C1958V2 whose expression is markedly elevated in pancreatic cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of pancreatic cancer, and as target molecules for developing drugs against the disease.
    Type: Grant
    Filed: August 31, 2009
    Date of Patent: May 17, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Toyomasa Katagiri
  • Breast cancer related gene ZNFN3A1
    Patent number: 7939254
    Abstract: Objective methods for detecting and diagnosing breast cancer (BRC) are described herein. Also described are methods of treating and preventing breast cancer and breast cancer metastasis as well as methods of assessing the prognosis of a breast cancer subject and the efficacy of a breast cancer therapy. In one embodiment, the diagnostic method involves determining the expression level of ZNFN3A1, a gene whose expression is markedly elevated in breast cancers, that therefore can be used to discriminate between BRC cells and normal cells. The present invention further provides methods of screening for therapeutic agents useful in the treatment of BRC, methods of treating BRC and method for vaccinating a subject against BRC.
    Type: Grant
    Filed: February 9, 2006
    Date of Patent: May 10, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Shuichi Nakatsuru
  • C2ORF18 AS TARGET GENE FOR CANCER THERAPY AND DIAGNOSIS
    Publication number: 20110098339
    Abstract: Described herein are objective methods for detecting or diagnosing a predisposition to developing cancer, particularly pancreatic cancer. In one embodiment, the diagnostic method involves the step of determining an expression level of C2orf18 using anti-C2orf18 antibody. The present invention further provides methods of screening for therapeutic agents useful in the treatment of a C2orf18-associated disease, such as a cancer, e.g. pancreatic cancer, methods of inhibiting the cell growth and treating or alleviating their symptom. The invention also features products, such as polynucleotides, polypeptides, and vectors double-stranded molecules, antibodies, vectors and compositions composed thereof.
    Type: Application
    Filed: March 10, 2009
    Publication date: April 28, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Hidewaki Nakagawa, Shuichi Nakatsuru
  • COMBINATION THERAPY FOR PANCREATIC CANCER USING AN ANTIGENIC PEPTIDE AND CHEMOTHERAPEUTIC AGENT
    Publication number: 20110082088
    Abstract: Described herein is a combination therapy suited to the treatment of pancreatic cancer and the like. Also described is a method of potentiating the therapeutic effect of chemotherapeutic agents such as gemcitabine.
    Type: Application
    Filed: August 19, 2008
    Publication date: April 7, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventor: Hiroki Yamaue
  • Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides
    Patent number: 7919099
    Abstract: The present invention provides immunogenic peptides comprising the amino acid sequence of SEQ ID NO: 1, 2, 13, 32, and peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted or added, and having cytotoxic T cell inducibility, and also provides drugs for treating or preventing tumors comprising these peptides. The peptides of this invention can be used as vaccines.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: April 5, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Takuya Tsunoda, Masabumi Shibuya, Shuichi Nakatsuru
  • DKK1 ONCOGENE AS THERAPEUTIC TARGET FOR CANCER AND A DIAGNOSING MARKER
    Publication number: 20110076280
    Abstract: Described herein are antibodies and antibody fragments capable of treating or preventing cancers associated with the over-expression and/or up-regulation of DKK1. Also disclosed are methods of treating or preventing cancer using the antibody and methods and kits utilized to diagnosing cancer. The herein described products and methods find utility in the context of a variety of cancers, such as pancreatic cancer, gastric cancer, liver cancer, prostate cancer, breast cancer, cervical cancer, bile duct cancer, lung cancer and esophageal cancer.
    Type: Application
    Filed: August 21, 2008
    Publication date: March 31, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventor: Yusuke Nakamura
  • IMP-1 ONCOGENE AS A THERAPEUTIC TARGET AND PROGNOSTIC INDICATOR FOR LUNG CANCER
    Publication number: 20110070245
    Abstract: IMP-1 was abundantly expressed in the majority of lung-cancers examined. Positive immunostaining of IMP-1 was correlated with tumor size (pT-classification; P=0.0003), non-adenocarcinoma histology (P<0.0001), low-histological grade (P=0.0001), and poor prognosis (P=0.0053). Suppression of IMP-1 expression with siRNA effectively suppressed growth of NSCLC cells. IMP-1 was able to bind to mRNAs encoding a variety of proteins involved in signal transduction, cell-cycle progression, cell adhesion and cytoskeleton, and various types of enzymatic activities. These results suggest that IMP-1 expression is likely to play important roles in lung cancer development and progression, and that IMP-1 is a prognostic marker and a promising therapeutic target for treatment of lung cancer.
    Type: Application
    Filed: August 16, 2007
    Publication date: March 24, 2011
    Applicant: ONCOTHERAPY SCIENCE INC.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • STAT3 EPITOPE PEPTIDES
    Publication number: 20110052614
    Abstract: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 16, 17, 19, 20, 21, 22, 26, 27, 29, 30, 59, 61, 63, 64, 65, 66, 67, 68, 69, 70, 72, 73, 74, 75, 77, 83, 94, 96, 97, 98 or 103, and peptides comprising one of the above-mentioned amino acid sequences with substitution or addition of one, two, or several amino acids, and having cytotoxic T cell inducibility, and also provides drugs comprising these peptides. The peptides of this invention can be used as vaccines.
    Type: Application
    Filed: November 27, 2008
    Publication date: March 3, 2011
    Applicant: Oncotherapy Science Inc.
    Inventors: Takuya Tsunoda, Ryuji Osawa
  • Method for diagnosing non-small cell lung cancers by tRNA-dihydrouridine synthase activity of
    Patent number: 7897329
    Abstract: The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for diagnosing non-small cell lung cancer (NSCLC) using the t-RNA dihydrouridine-synthase activity of IMS-E21 (URLC8) protein as an index. The present invention further provides methods for predicting and prognosing lung squamous-cell carcinoma (SCC).
    Type: Grant
    Filed: September 21, 2005
    Date of Patent: March 1, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • METHOD FOR TREATING SYNOVIAL SARCOMA
    Publication number: 20110027289
    Abstract: Methods of detecting synovial sarcoma using differentially expressed genes are disclosed. Also disclosed are methods of identifying agents for treating synovial sarcoma. Further, a method for treating or preventing a disease that is associated with Frizzled homologue 10 (FZD10) in a subject is provided.
    Type: Application
    Filed: April 28, 2010
    Publication date: February 3, 2011
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Yusuke NAKAMURA, Toyomasa Katagiri, Chikako Fukukawa
  • PEPTIDE VACCINES FOR LUNG CANCERS EXPRESSING TTK, URLC10 OR KOC1 POLYPEPTIDES
    Publication number: 20110027302
    Abstract: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.
    Type: Application
    Filed: October 13, 2010
    Publication date: February 3, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Takuya Tsunoda, Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8
    Publication number: 20110014615
    Abstract: The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for diagnosing non-small cell lung cancer (NSCLC) using the t-RNA dihydrouridine-synthase activity of IMS-E21 (URLC8) protein as an index. The present invention further provides methods for predicting and prognosing lung squamous-cell carcinoma (SCC).
    Type: Application
    Filed: May 18, 2010
    Publication date: January 20, 2011
    Applicant: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • Hepatocellular carcinoma-related genes and polypeptides, and method for detecting hepatocellular carcinomas
    Patent number: 7871763
    Abstract: Genes up-regulated in hepatocellular carcinomas and polypeptides encoded by these genes are provided. Vectors, transformants and methods for producing the recombinant polypeptides are also provided. Probes and primers of these genes and antibodies against the polypeptides are also provided. The probes, primers and antibodies can be used as reagents for detecting hepatocellular carcinomas. Methods for detecting hepatocellular carcinomas using such detection reagents are further provided. Antisense nucleotide sequences of these genes are also provided and can be used to inhibit growth of hepatocellular carcinomas.
    Type: Grant
    Filed: January 16, 2008
    Date of Patent: January 18, 2011
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa
  • CXADRL1 polypeptides relating to human cancers
    Patent number: 7847065
    Abstract: The present application provides novel human genes RNF43 whose expression is markedly elevated in colorectal cancers, as well as CXADRL1 and GCUD1 whose expression is markedly elevated in gastric cancers compared to corresponding non-cancerous tissues. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease.
    Type: Grant
    Filed: July 17, 2008
    Date of Patent: December 7, 2010
    Assignee: Oncotherapy Science, Inc.
    Inventors: Yusuke Nakamura, Yoichi Furukawa, Hideaki Tahara, Takuya Tsunoda
  • Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
    Patent number: 7847060
    Abstract: The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 8, 67, 89, as well as peptides comprising the above-mentioned amino acid sequences in which 1, 2, or several amino acids are substituted, deleted, or added, and having cytotoxic T cell inducibility. The present invention also provides drugs for treating or preventing tumors comprising these peptides. The peptides of the present invention can also be used as vaccines.
    Type: Grant
    Filed: February 17, 2006
    Date of Patent: December 7, 2010
    Assignee: Oncotherapy Science, Inc.
    Inventors: Hideaki Tahara, Takuya Tsunoda, Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru
  • CANCER ASSOCIATED GENE LY6K
    Publication number: 20100291091
    Abstract: LY6K is identified herein as a potential biomarker useful for the diagnosis of cancer, such as lung and esophageal cancers, as well as for the prognosis of patients with these diseases. As discussed in detail herein, LY6K is specifically over-expressed in most lung and esophageal cancer tissues examined, and is elevated in the sera of a large proportion of patients with these tumors. Accordingly, LY6K may be used in combination with other tumor markers to significantly improve the sensitivity of cancer diagnosis. LY6K may be used in the treatment of ESCC cells, as demonstrated by the fact that small interfering RNAs (siRNAs) of LY6K suppressed growth of the cancer cells. Moreover, the LY6K molecule is also a likely candidate for development of novel therapeutic approaches, such as antibody therapy.
    Type: Application
    Filed: November 21, 2007
    Publication date: November 18, 2010
    Applicant: ONCOTHERAPY SCIENCE ,inc.
    Inventors: Yusuke Nakamura, Yataro Daigo, Shuichi Nakatsuru